Background {#Sec1}
==========

*Staphylococcus aureus* (*S. aureus*) has established itself over the years as a major cause of morbidity and mortality globally both within the community and in healthcare settings \[[@CR1]--[@CR3]\]. Its ability to cause disease is aided not only by its impressive repertoire of virulence factors but also its ability to develop resistance to antibiotics used in its treatment epitomized by the emergence of methicillin resistant *S. aureus* (MRSA). Methicillin resistance is conferred by the *mecA* gene that is carried on a staphylococcal cassette chromosome *mec* (SCC*mec*) and codes for a modified penicillin binding protein (PBP2a). This binding protein has reduced affinity to all beta-lactam and beta-lactam/beta-lactamase inhibitor combination antibiotics \[[@CR4], [@CR5]\]. In Africa, the MRSA prevalence has been shown to vary across different countries with a prevalence as low as 7 % reported in Madagascar and as high as 82 % in Egypt \[[@CR6]\]. This marked variation could be due to different environmental determinants or simply due to a difference in the genetic diversity of *S. aureus*. In Kenya, there is a marked difference in reported MRSA prevalence in clinical isolates within Nairobi with one recent study reporting a prevalence of 3.7 % while another reported 87.2 % \[[@CR7], [@CR8]\]. In order to better understand the epidemiology of MRSA, it is important to define its population structure. Molecular characterization helps in identifying clonal populations which can help in surveillance and investigation of outbreaks.

There is a growing interest in the characterization of MRSA isolates and this stems primarily from its role as a major cause of hospital and community acquired infections \[[@CR1], [@CR9], [@CR10]\]. There are various molecular methods used, the more common ones include multi-locus sequence typing (MLST), pulse field gel electrophoresis (PFGE), staphylococcal protein A (*spa*) typing and SCC*mec* typing \[[@CR11]\]. Despite *S. aureus* having a very diverse clonal population, MLST studies have shown that a small set of clonal complexes (CC) are associated with most of the MRSA epidemics. These include CC5, CC22, CC30, CC45 and CC80 \[[@CR6], [@CR12], [@CR13]\]. A clonal complex can have several sequence types, however the multi-locus sequence types that are regarded as the founders in these clonal complexes are ST5, ST22, ST30, ST45 and ST80 respectively \[[@CR14]\]. As regards *spa* types, it has been shown that particular ones are more predominant in certain regions. For example t030 is quite predominant in hospitals in Turkey \[[@CR15]\], t042 and t044 are more common in North Africa while t008 is common in the US \[[@CR16]\]. Unfortunately, the molecular epidemiology of MRSA in Africa is not very well described. Most of the studies carried out in Africa characterizing MRSA have emanated from a few countries namely Tunisia, Nigeria, South Africa, Algeria and Egypt \[[@CR6]\]. There are very few studies from East Africa that have reported on the molecular characterization of *S. aureus* presumably due to lack of readily available technical expertise and laboratory facilities. A study done in Kenya looking at carriage of *S. aureus* by inpatients in a government hospital found that only 6 out of 86 (7 %) *S. aureus* isolates were MRSA and they all belonged to the same clone (MLST ST239; *spa* type t037) \[[@CR17]\]. This clone is a globally distributed hybrid of ST8 and ST30 and is known to be responsible for several outbreaks in different continents \[[@CR18]--[@CR21]\]. The only other study from Kenya did not report on *spa* or multi locus sequence types \[[@CR8]\].

We set out to characterize selected *S. aureus* isolates from different hospitals in Nairobi, Kenya in order to identify which clonal lineages are present and further shed light on the molecular epidemiology of both MSSA and MRSA in Kenya.

Methods {#Sec2}
-------

We obtained archived methicillin susceptible (MSSA) and MRSA isolates from 2 hospitals in Nairobi, Kenya collected between January 2010 and July 2013. The hospitals included a government hospital whose samples we obtained through the Kenya Medical Research Institute (KEMRI) and the Aga Khan University Hospital Nairobi (AKUHN) which is a private referral hospital with a network of satellite clinics and laboratories spread in and around Nairobi as well as different parts of the country. The isolates from the government hospital were part of a previous study done to determine prevalence of MRSA carriage in a paediatric ward and the rest of the isolates were from clinical specimens submitted to the AKUHN laboratory for routine culture and sensitivity. These were convenience isolates that were not collected through a well-structured, formal and documented process. All isolates were stored at −80 °C and grown overnight on sheep blood agar plates at 37 °C.

*S. aureus* identification {#Sec3}
--------------------------

All isolates were confirmed to be *S. aureus* using routine bench identification methods which included growth characteristics on sheep blood agar, gram stain, catalase, coagulase, deoxyribonuclease (DNase) and mannitol fermentation tests. A cefoxitin screen using a 30 µg disc (Oxoid, United Kingdom) was performed to distinguish MSSA from MRSA. Isolates with a diameter ≤21 mm were classified as MRSA.

Antibiotic susceptibility {#Sec4}
-------------------------

Antibiotic susceptibility was only available for the MRSA isolates obtained from AKUHN. These were performed on Vitek 2 (version 4.01, bioMerieux, Marcy-l'Etoile, France) an automated bacterial identification system that performs antibiotic susceptibility using broth dilution and interpretation based on Clinical Laboratory Standards Institute (CLSI) antimicrobial susceptibility guidelines \[[@CR22]\]. Multidrug resistance (MDR) was defined as resistance to three or more drug classes.

DNA derivation {#Sec5}
--------------

Isolates were grown on blood agar plates (National Health Laboratory Services Media Lab, Cape Town, South Africa) at 37 °C overnight. After incubation, 4--5 large colonies were re-suspended in 200 µL nuclease free water. The samples were incubated at 95 °C for 30 min, followed by −80 °C for 30 min and centrifuged for 10 min at 14,000×*g* when thawed. The supernatant containing DNA was carefully aspirated without disturbing the pellet of cell debris and stored as DNA aliquots at −20° C until further use.

PFGE {#Sec6}
----

PFGE based on *Sma*I macrorestriction analysis was performed using the CDC laboratory protocol for *S. aureus* \[[@CR23]\]. The PFGE was run on a CHEF DR III system (Bio-Rad, California, United States of America) with optimum settings as follows: initial 5 s, switch 30 s, run time 29 h, voltage 6 V/cm and a SeaKem Gold agarose (Lonza, Rockland, USA) gel concentration of 1.4 %. *S. aureus* NCTC 8325 was used as a control in each gel run. Gels were visualized an Alliance 2.7 (UVItec, Cambridge, United Kingdom) gel documentation system after staining with 10 mg/mL ethidium bromide. Analysis of PFGE clusters was performed using the BioNumerics software package (Applied Maths, Sint-Martens-Latem, Belgium), using the Dice coefficient, and visualized as a dendrogram by the unweighted-pair group method, using average linkages with 1 % tolerance and 1 % optimization settings. In order to define a cluster, a cutoff of 80 % similarity was used.

SCC*mec* typing {#Sec7}
---------------

SCC*mec* typing was performed using multiplex PCR as described by Milheirico et al. \[[@CR24]\]. All assays were performed in a GeneAmp 9600 thermocycler (Applied Biosystems). The optimal cycling conditions were the following: 95 °C for 5 min; 35 cycles of 95 °C for 45 s, 57 °C for 45 s, and 72 °C for 1 min; and a final extension at 72 °C for 10 min. Each PCR mixture contained 0.5 µL of the primers listed in Table [1](#Tab1){ref-type="table"}, KAPA2G Robust HotStart ReadyMix PCR (KAPA biosystems) which contains KAPA2G Robust HotStart DNA Polymerase (1 U/25 µL reaction) in a proprietary reaction buffer containing dNTPs (0.2 mM of each dNTP at 1X), MgCl~2~ (2 mM at 1X), 0.3 µL (3 mM) additional MgCl~2~, 10.7 µL of PCR grade water and genomic DNA in a final volume of 25 µL. The following *S. aureus* isolates were used as controls: BAA-38, BAA-1681, BAA-39, BAA-1680, BAA-1688 and BAA-42 for SCC*mec* types I--VI respectively. The PCR products were resolved in a 1 % SeaKem Gold Agarose (Lonza, Rockland, USA) gel in 0.5 % Tris--borate-ethylene-diamine-tetra-acetic acid (EDTA) buffer (Bio-Rad, Hercules, CA) at 4 V/cm for 2.5 h and were visualized with ethidium bromide.Table 1Primers used in the updated version of SCC*mec* multiplex PCRPrimer namePrimer sequence (5 33)Primer specificity (SCC*mec* type, region)Amplicon size (bp)Conc. (µM)CIF2 F2TTCGAGTTGCTGATGAAGAAGGI, J1 region4950.4CIF2 R2ATTTACCACAAGGACTACCAGC0.4ccrC F2GTACTCGTTACAATGTTTGGV, *ccr* complex4490.8ccrC R2ATAATGGCTTCATGCTTACC0.8RIF5 F10TTCTTAAGTACACGCTGAATCGIII, J3 region4140.4RIF5 R13ATGGAGATGAATTACAAGGG0.4SCCmec V J1 FTTCTCCATTCTTGTTCATCCV, J1 region3770.4SCCmec V J1 RAGAGACTACTGACTTAAGTGG0.4dcs F2CATCCTATGATAGCTTGGTCI, II, IV, and VI, J3 region3420.8dcs R1CTAAATCATAGCCATGACCG0.8ccrB2 F2AGTTTCTCAGAATTCGAACGII and IV, *ccr* complex3110.8ccrB2 R2CCGATATAGAAWGGGTTAGC0.8kdp F1AATCATCTGCCATTGGTGATGCII, J1 region2840.2kdp R1CGAATGAAGTGAAAGAAAGTGG0.2SCCmec III J1 FCATTTGTGAAACACAGTACGIII, J1 region2430.4SCCmec III J1 RGTTATTGAGACTCCTAAAGC0.4mecI P2ATCAAGACTTGCATTCAGGCII and III, *mec* complex2090.8mecI P3GCGGTTTCAATTCACTTGTC0.8mecA P4TCCAGATTACAACTTCACCAGGInternal positive control1620.8mecA P7CCACTTCATATCTTGTAACG0.8

*spa* typing {#Sec8}
------------

This was done using the following primers: 1095 F: 5′-AGACGATCCTTCGGTGAGC-3′ and 1517R: 5′-GCTTTTGCAATGTCATTTACTG-3′. PCR reactions consisted of 12.5 uL of KAPA2G Robust HotStart ReadyMix PCR (KAPA biosystems) which contains KAPA2G Robust HotStart DNA Polymerase (1 U per 25 µL reaction) in a proprietary reaction buffer containing dNTPs (0.2 mM of each dNTP at 1X), MgCl2 (2 mM at 1X), 0.5 μM of primers and genomic DNA in a final volume of 25 µL. PCR conditions were 95 °C for 6 min; 30 cycles each of 95 °C for 45 s, 64 °C for 45 s, and 72 °C for 60 s; and a final extension at 72 °C for 6 min. Sequencing was outsourced to inqaba biotec, a biotechnology company based in Pretoria, South Africa. Using the Ridom *spa* server (<http://www.spa.server.ridom.de>), *spa* sequences were automatically assigned to *spa* types. Sequence types and clonal complexes (*sp*a-CC) were assigned where possible using Based Upon Repeat Patterns (BURP) grouping analysis from the Ridom StaphType software (version 1.4; Ridom GmbH, Würzburg, Germany). For BURP analysis, default parameters were used which allows *spa* types with maximum 4 genetic differences to be grouped into one cluster resulting in a calculated cost between members of a group being less than or equal to 4.

MLST {#Sec9}
----

MLST was done on representative isolates from each PFGE clonal complex and selected singletons according to the protocol published by Enright et al. \[[@CR25]\]. The PCRs were carried out as uniplex reactions consisting of 1 µM of the forward and reverse primers, 12.5 µL of 2× KAPA Taq ReadyMix (KAPA Biosystems), 2.5 mM MgCl~2~, 1 µL of template DNA and nuclease free water up to 25 µL. The PCR conditions were 95 °C for 5 min, followed by 30 cycles of 95 °C for 45 s, 56 °C for 45 s and 72 °C for 1 min. A final elongation step was carried out at 72 °C for 10 min. 5 µL of the PCR product was visualised with gel electrophoresis at 120 V for 1 h. Sequencing was performed on the remainder of the PCR product by Inqaba Biotechnical Industries (Pty) Ltd (Pretoria, South Africa). Sequences were inspected and trimmed in BioEdit Sequence Alignment Editor using reference sequences for each of the seven loci. A consensus sequence was generated from the forward and reverse sequences and used to generate sequence types (STs) on the *S. aureus* MLST database ([http://www.saureus.beta.mlst.net/\#](http://www.saureus.beta.mlst.net/%23)). Isolates that were not typed by MLST were assigned STs using BURP analysis. Isolates with the same PFGE clonal complex and *spa* type were assigned the same STs. MLST clonal complexes (MLST-CC) were determined using a Java applet found at <http://www.eburst.mlst.net> that uses the eBURST algorithm. The default setting was used in which STs that share identical alleles at 6 or 7 of MLST loci are put in the same group. Where there was a discrepancy between the CC determined using eBURST and BURP, we considered the MLST-CC as the correct one.

Results {#Sec10}
=======

A total of 93 *S. aureus* isolates underwent PFGE. These were subsequently grouped into 19 PFGE clonal complexes (A--S) and 12 singletons. From these, 55 (32 MRSA and 23 MSSA) representative isolates from each PFGE clonal complex and all singletons were *spa* typed. This comprised 41 isolates from AKUHN and 14 from KEMRI. In total, there were 18 different MRSA *spa* types and 22 different *spa* types amongst the MSSA. The predominant MRSA *spa* type was t037 comprising 40.6 % (13/32) of all MRSA. In contrast, the MSSA were quite heterogeneous, only 2 out of 23 MSSA shared the same *spa* type. Two new MRSA *spa* types (t13149 and t13150) and 3 new MSSA *spa* types (t13182, t13193, t13194) were identified as shown in Table [2](#Tab2){ref-type="table"}. Three *spa* types (t005, t318 and t1476) were found in both MSSA and MRSA. BURP analysis for both MSSA and MRSA revealed 7 spa-clonal complexes and 14 singletons as shown in Fig. [1](#Fig1){ref-type="fig"}. The predominant *spa*-CC was *spa*-CC005 which included the new MRSA *spa* type 13149. SCC*mec* type-III \[3A\] was the predominant type followed by SCC*mec*-IV \[2B\]. Only one MRSA isolate was non-typeable using the SCC*mec* protocol published by Milheirico et al. \[[@CR24]\]Table 2Molecular characterization of methicillin susceptible and resistant *Staphylococcus aureus*Isolate No.HospitalSampleID*spa* type*spa*-CCSCC*mec* typeMLST/*spa* STMLST CCPFGE CCPFGE pulsotype36AKUHNPus swabMSSAt645sng1841^a^121AA284AKUHNPus swabMSSAt314sng121^a^121BB278AKUHNPus swabMSSAt355sng152^a^152CC148AKUHNPus swabMSSAt355sng152^b^152CC491AKUHNNasal swabMRSAt0055IV22^a^22DD228AKUHNNasal swabMRSAt0055IV22^b^22DD383AKUHNSputumMRSAt0055IV22^b^22DD389AKUHNPus swabMRSAt13149^d^5IVND^c^DD122KEMRINasal swabMRSAt0225IV22^a^22EE275AKUHNBloodMRSAt9622sngIVND^c^EE115AKUHNPus swabMSSAt005522^a^22FF612AKUHNPus swabMSSAt223522^a^22GG271AKUHNPus swabMSSAt122sng30^a^30HH188AKUHNTracheal aspirateMSSAt318sng30^a^30II516AKUHNPus swabMSSAt0212130^a^30II723AKUHNSputumMRSAt13393202/186UT88^a^88JJ249KEMRINasal swabMRSAt32023202/186UTND^c^JJ119AKUHNAxillary swabMSSAt3841sng672^a^672KK26AKUHNNasal swabMRSAt091NF3V789^a^7LL269AKUHNPus swabMSSAt2505NF3789^a^7LL114AKUHNTracheal aspirateMSSAt002sng5^a^5MM379AKUHNPus swabMRSAt13150^d^sngII5^a^5MM252AKUHNBloodMSSAt2473sng72^a^72NN392AKUHNBloodMSSAt13193^d^522^a^22OO187AKUHNBloodMSSAt127sng1^a^5PP381AKUHNEar swabMRSAt1476NF2V8^a^5QQ145AKUHNPus swabMSSAt1476NF28^a^5QQ231AKUHNPus swabMSSAt064sng8^a^5RR433KEMRINasal swabMRSAt104NF1IV8^a^5RR27KEMRINasal swabMRSAt689NF1IND^c^RR125AKUHNBloodMRSAt8525IVND^c^RR54AKUHNSputumMRSAt037NF4III241^a^5SS12KEMRINasal swabMRSAt037NF4III241^b^5SS103KEMRINasal swabMRSAt037NF4III241^b^5SS101AKUHNBloodMRSAt037NF4III241^b^5SS1147KEMRINasal swabMRSAt037NF4III241^b^5SS238KEMRINasal swabMRSAt037NF4III241^b^5SS334KEMRINasal swabMRSAt037NF4III241^b^5SS420KEMRINasal swabMRSAt037NF4III241^b^5SS518KEMRINasal swabMRSAt037NF4III241^b^5SS637KEMRINasal swabMRSAt037NF4III241^b^5SS727KEMRINasal swabMRSAt037NF4III241^b^5SS929AKUHNPus swabMRSAt2029NF4IV241^a^5SS813AKUHNPus swabMRSAt037NF4III239/240/241^c^Sng1211AKUHNPus swabMRSAt037NF4III239/240/241^c^Sng617AKUHNPus swabMSSAt13182^d^sngND^c^Sng 344AKUHNUrineMSSAt13194^d^sngND^c^Sng773AKUHNPus swabMSSAt1839345ND^c^Sng558AKUHNBloodMSSAt1863202/18688^c^Sng470AKUHNBloodMSSAt22434597^c^Sng821AKUHNPus swabMRSAt293sngIVND^c^Sng 243KEMRINASAL SWABMRSAt318sngIV30^c^Sng 135AKUHNPus swabMRSAt345345VND^c^Sng1040AKUHNUrineMRSAt648NF2IVND^c^Sng1185AKUHNVulval swabMSSAt131345ND^c^Sng9*sng* singleton, *NF* no founder, *UT* untypeable, *ND* not defined on the Ridom database Accessed on 07/10/2015^a^MLST ST^b^MLST ST extrapolated based on similar *spa* type and pulsotype^c^ *spa* ST^d^New *spa* typeFig. 1Based upon repeat pattern clustering analysis for all identified *S. aureus* isolates: the clustering analysis resulted in seven *spa*-clonal complexes and 14 singletons. The *blue circle* represents the group founder and the circle size is proportional to the frequency of the *spa* type

MLST STs were determined and extrapolated for 31 isolates. A total of seven different MRSA and MSSA MLST-CC were identified with the predominant one being MLST-CC 5. This clonal complex comprised STs 1, 5, 8 and 241 as shown in Table [2](#Tab2){ref-type="table"}. An isolate belonging to ST241 (t2029) that was detected in a pus sample from AKUHN hospital was found to harbor SCC*mec* type IV \[2B\].

Out of the 16 MRSA from AKUHN, 13 were MDR including the two new *spa* types. Resistance was commonly seen to clindamycin, erythromycin and trimethoprim/sulfamethoxazole (TMP/SMX). A number of isolates had intermediate resistance to levofloxacin. However, two isolates were only resistant to beta lactams but susceptible to all other antibiotics including TMP/SMX as shown in Table [3](#Tab3){ref-type="table"}. None of the MRSA was resistant to vancomycin, linezolid, mupirocin, teicoplanin or tigecycline.Table 3Molecular characterization and antibiotic susceptibility of MRSA isolates from AKUHNIsolate No.Sample*spa* typeSCC*mec* typeAntibiogramRSI21Pus swabt293IV \[2B\]TOB, CLI, ERY, LEVLNZ, TEI, VAN, TET, TIG, MUP, RIF, SXT, MOX23Sputumt1339UTSXTTOB, MOX, ERY, CLI, VAN, TET, TIG, MUP, RIF, LEV79Pus swabt13150^a^II \[2A\]ERY, CLI, LEV, MOX, TOBTET, SXT, VAN, MUP, RIF, TIG, TEI, LNZ40Urinet648IV \[2B\]--ERY, CLI, TET, SXT, VAN, MUP, MOX, RIF, TIG, TOB, TEI, LNZ, LEV25Bloodt852IV \[2B\]CLI^\#^, ERYLNZ, MUP, MOX, RIF, SXT, TET, TEI, TIG, TOB, VANLEV35Pus swabt345V \[5C\]RIF, SXT, TET, TOBCLI, ERY, LNZ, MUP, MOX, TEI, TIG, VANLEV13Pus swabt037III \[3A\]CLI, ERY, SXT, TOBLNZ, MUP, MOX, RIF, TET, TEI, TIG, VANLEV11Pus swabt037III \[3A\]CLI^\#^, SXT, TET, TOBERY, LNZ, MUP, MOX, RIF, TEI, TIG, VANLEV89Pus swabt13149^a^IV \[2B\]TOB, SXT, ERYCLI, LNZ, TEI, VAN, TET, TIG, MUP, RIF, LEV, MOX75Bloodt9622IV \[2B\]--ERY, CLI, TET, SXT, VAN, MUP, MOX, RIF, TIG, TOB, TEI, LNZLEV83Sputumt005IV \[2B\]TOB, ERY, CLI^\#^MOX, LNZ, TEI, VAN, TET, TIG, MUP, RIF, SXTLEV28Nasal swabt005IV \[2B\]ERY, CLI^\#^, TOB, LEVTET, SXT, VAN, LNZ, TEI, MUP, MOX, RIF, TIG81Ear swabt1476V \[5C\]ERY, CLI^\#^, TET, SXT, LEVVAN, MUP, MOX, RIF, TIG, TEI, LNZTOB6Nasal swabt091V \[5C\]SXT, TET, TOBCLI, ERY, LNZ, MUP, MOX, RIF, TEI, TIG, VANLEV29Pus swabt2029IV \[2B\]CLI, ERY, RIF, SXT, TET, TOBLNZ, MUP, MOX, TEI, TIG, VANLEV1Bloodt037III \[3A\]ERY, CLI^\#^, TET, SXT, RIF, TOB, LEVVAN, MUP, MOX, TIG, TEI, LNZ*R* resistant, S susceptible, *I* intermediate, *ERY* erythromycin, *CLI* clindamycin, *CLI* ^*\#*^ inducible clindamycin resistance, *TET* tetracycline, *SXT* trimethoprim/sulfamethoxazole, *VAN* vancomycin, *GENT* gentamicin, *MUP* mupirocin, *MOX* moxifloxacin, *RIF* rifampicin, *TIG* tigecycline, *TOB* tobramycin, *TEI* teicoplanin, *LNZ* linezolid, *LEV* levofloxacin^a^New spa type

Discussion {#Sec11}
==========

This study reveals a markedly heterogeneous population of *S. aureus* isolates as well as the presence of well described MRSA clonal complexes 5, 22 and 30 that are responsible for several outbreaks worldwide \[[@CR13], [@CR26]\]. CC5 has been identified as the major clonal complex causing HA-MRSA in Africa with MRSA ST239/ST241-III \[3A\] having been identified in several African countries \[[@CR6]\]. The main clonal complex in our study was CC5 that included ST 241, a single locus variant of ST 239 also known as the "Brazilian/Hungarian clone". ST 239 and ST 239 like isolates are well-known epidemic clones responsible for several healthcare associated MRSA outbreaks globally. They have been found to be a cause of hospital acquired infections in other African countries including Algeria, Ghana, Morocco, South Africa and Nigeria \[[@CR6]\]. A study done by Aiken et al. \[[@CR17]\] in a public hospital that is approximately 40 km from Nairobi identified t037-ST239 as the predominant clone carried by inpatients in a surgical ward. Most of the nasal swabs in our study were obtained from children in a paediatric ward situated in a public referral hospital. The high proportion of t037-ST241 among our MRSA isolates is not necessarily reflective of the true prevalence of this *spa* type in Nairobi due to a selection bias in the manner in which the isolates were collected. Nevertheless, it is quite concerning that a clone known to be associated with MRSA epidemics is resident within hospitals in Nairobi indicating an urgent need for proper infection control interventions and regular surveillance.

Unlike the study by Aiken et al. \[[@CR17]\] that only found one MRSA clone, we identified 18 distinct *spa* types amongst the MRSA isolates belonging to very diverse sequence types, including 2 MRSA *spa* types (t13149 and t13150) that have not previously been described. The *spa* type t13150 was found to belong to ST5-II \[2A\] which has also been found in Nigeria and Senegal \[[@CR27], [@CR28]\]. We identified MRSA belonging to ST22 which in Africa has only previously been found in Algeria, Tunisia and South Africa. This clone has been widely associated with hospital epidemics especially in new born units \[[@CR29]\]. The "West Australia MRSA-2 clone" (WA-MRSA-2), ST88-IV \[2B\] which has been reported in Cameroon and Madagascar was not found and the European MRSA clone ST80-IV that has been found in North African countries was not present in our collection. None of the MRSA in this study belonged to *spa* type t008, the prevalent *spa* type associated with the USA300 pulsotype that has been identified as the major cause of community acquired skin and soft tissue infections in North America \[[@CR30], [@CR31]\]. Although the isolates included in our study were few, they represent a fairly diverse collection from both a public and private referral hospital and we can therefore conclude that USA300 is not common in Nairobi.

The 23 MSSA belonged to 22 different *spa* types highlighting their marked genetic diversity in contrast to the MRSA. There were 3 *spa* types (t005, t318 and t1476) that were found in both MSSA and MRSA suggesting the possibility of local acquisition of an SCC*mec* element. One of the MSSA *spa* types belongs to t002 which is associated with the MRSA pulsotype USA100 \[[@CR16]\]. The *spa* type t064 was also found which is associated with one of the major MRSA clones (ST612- SCC*mec* IV \[2B\] found in South Africa \[[@CR32]\]. ST241 has frequently been associated with SCC*mec* III \[3A\], however, one isolate belonging to ST241 harbored SCCmec IV \[2B\] (this SCC*mec* element was more common in AKUHN hospital). This particular clone was previously observed in a large university clinic in Nigeria \[[@CR33]\]. SCC*mec* types IV and V are small in size and can be transmitted both in the community and healthcare settings. Potentially, this could result in the emergence of well-known epidemic MRSA clones like the predominant European CA-MRSA clone ST80-IV \[2B\] whose for bearer is thought to be a PVL-positive MSSA from sub-Saharan Africa that acquired the SCC*mec* IV \[2B\] \[[@CR34]\]. The MSSA strain t021-ST30 has also been associated with a known PVL positive CA-MRSA clone \[[@CR35]\].

The multi-drug resistant patterns for the MRSA in this study are in keeping with what has been described in other countries in Africa \[[@CR17], [@CR32], [@CR36], [@CR37]\]. Most of the MRSA were resistant to macrolide--lincosamide, tetracycline and sulphonamide group of antibiotics which is fairly common amongst MRSA especially those that are healthcare associated. However two of the isolates showed resistance to only beta lactam antibiotics suggesting that they may be community acquired (based on their molecular structure) given that they belonged to SCC*mec* type IV which has been associated with CA-MRSA.

The major limitation of this study is that the isolates characterized were not collected in a structured and consistent manner and as such the proportions reported do not necessarily represent a true picture of the relative distributions of different clones in Nairobi due to a selection bias. The over representation of nasal swab specimens from a paediatric population from one hospital may have exaggerated the prevalence of t037-ST 241. We also did not carry out MLST and *spa* typing on all isolates due to financial constraints. However, we did ensure that a representative isolate from each PFGE clonal complex was included in the isolates that were further characterized using MLST and *spa* typing.

Conclusion {#Sec12}
==========

To the best of our knowledge, this is the largest study from Kenya that has carried out PFGE, MLST, *spa* and SCC*mec* typing on a diverse collection of MRSA isolates. This study highlights the marked genetic diversity of MSSA and MRSA isolates in Nairobi including the presence of well-known epidemic MRSA clones and new MRSA *spa* types. Given the evolution of *S. aureus* over the years, there is need for continuous surveillance in order to keep track of emerging clones. The existence of epidemic MRSA clones further justifies the need to strengthen infection control measures within our hospitals so as to avoid nosocomial *S. aureus* infections.
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